RENO, Nev., Aug. 13, 2025 /CNW/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold", or the "Company") reports its operating and financial...
RENO, Nev., Aug. 13, 2025 /PRNewswire/ - i-80 GOLD CORP. (TSX: IAU) (NYSE American: IAUX) ("i-80 Gold", or the "Company") reports its operating and financial...
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
- Profitability initiatives drive margin expansion; Location count surpasses 1,000 early...
On 13 August 2025, the Management Board of AB “Ignitis grupė” (hereinafter – the Group or AB “Ignitis grupė”), legal entity code: 301844044, registered office address: Laisvės Ave. 10, Vilnius, decided to convene the General Meeting of Shareholders (hereinafter – GM) of the Group.
On 13 August 2025, the Management Board of AB “Ignitis grupė” (hereinafter – the Group or AB “Ignitis grupė”), legal entity code: 301844044, registered office address: Laisvės Ave. 10, Vilnius, decided to convene the General Meeting of Shareholders (hereinafter – GM) of the Group.
CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the second quarter of 2025. The Company’s interim financial statements for the three and six months ended June 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca.
CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto" or the "Company") is pleased to report operating and financial results for the second quarter of 2025.
VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...
IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results...